Covid Toes
Overview
COVID toes, medically known as COVID-associated chilblain-like lesions, refer to reddish or purplish discolorations, swelling, and sometimes blistering that appear on the toes, feet, or occasionally fingers in association with SARS-CoV-2 infection.
They were first recognized early in the COVID-19 pandemic (2020) and remain one of the most distinctive cutaneous manifestations linked to the disease.
Unlike the severe respiratory and systemic symptoms of COVID-19, COVID toes usually occur in otherwise healthy individuals, often children, adolescents, or young adults, and frequently in mild or asymptomatic cases.


Etiology (Cause and Pathophysiology)
The exact cause of COVID toes is not completely understood, but several mechanistic theories have emerged from histologic and immunologic studies.
1. Immune-Mediated Microvascular Inflammation
The leading hypothesis is that COVID toes represent a post-viral immune response rather than direct viral infection of the skin.
  • SARS-CoV-2 triggers a robust Type I interferon response, which enhances antiviral activity but simultaneously activates inflammatory cells around small blood vessels in the skin.
  • This results in endothelial swelling, perivascular lymphocytic infiltration, and vascular leakage, resembling chilblains seen after cold exposure.
2. Microangiopathy and Thrombotic Changes
  • SARS-CoV-2 infection can cause endothelial dysfunction and microthrombi formation in small dermal vessels.
  • This leads to ischemic changes and purple discoloration at distal extremities.
3. Delayed Hypersensitivity or Autoimmune Reaction
  • Some cases appear weeks after acute infection, consistent with a post-infectious immune phenomenon.
  • Elevated interferon and autoantibody activity have been identified in some patients.
4. Environmental and Host Factors
  • Cold or damp conditions may worsen or unmask lesions.
  • Genetic differences in immune response (interferon pathways) may explain why some individuals develop these lesions while others do not.


Clinical Features
Typical Presentation
  • Location: Toes (most common), occasionally fingers or soles.
  • Appearance: Red, purple, or violaceous macules, papules, or plaques; may blister, crust, or peel.
  • Symptoms: Itching, burning, tenderness, or mild pain.
  • Course: Develops days to weeks after viral exposure or recovery, usually self-limited.
Associated Findings
  • Most patients have mild or no systemic symptoms of COVID-19.
  • Lesions may appear when PCR testing is negative but serology is positive, suggesting prior infection.
Differential Diagnosis
  • Idiopathic pernio (cold-induced chilblains)
  • Lupus erythematosus
  • Small-vessel vasculitis
  • Acrocyanosis
  • Frostbite
Diagnosis
Diagnosis is primarily clinical, supported by:
  • History of COVID-19 infection or exposure.
  • Characteristic lesions in the appropriate setting.
  • Histopathology (if biopsy performed): Lymphocytic vasculitis, dermal edema, and endothelial activation consistent with chilblains.


Treatment
Most cases of COVID toes are self-limited and resolve without aggressive therapy.
The mainstay of management is supportive and symptomatic care.
Conservative Measures
  • Warmth and protection: Keep the affected areas warm and dry; avoid further cold exposure.
  • Topical corticosteroids: Mild to moderate potency (e.g., hydrocortisone 2.5%, triamcinolone 0.1%) to relieve inflammation, redness, and itching.
  • Pain control: Nonsteroidal anti-inflammatory drugs (NSAIDs) for discomfort or swelling.
  • Emollients or barrier creams: Help protect fragile skin and reduce dryness or fissuring.
Medical Therapies (for persistent or severe cases)
  • Topical or systemic calcium channel blockers (e.g., nifedipine) — may improve microcirculation and relieve vasospasm.
  • Short courses of systemic corticosteroids — reserved for severe inflammation or ulceration unresponsive to conservative care.
  • Antibiotics — only if secondary bacterial infection is suspected.
  • Referral to dermatology for biopsy or evaluation if lesions persist >8 weeks or diagnosis is uncertain.
Patient Education
  • Reassure patients that COVID toes are benign and transient.
  • Emphasize infection control measures and isolation guidelines if the patient is within an active or recent COVID-19 infection period.
  • Monitor for systemic symptoms of COVID-19 or other complications.


Expectations and Prognosis
  • Course: Most cases resolve spontaneously within 2–8 weeks.
  • Recurrence: Possible, especially during cold weather or with repeated viral exposure.
  • Complications: Rare; in occasional cases, lesions may ulcerate or become secondarily infected.
  • Prognosis: Excellent — most patients recover completely without scarring or chronic vascular issues.
  • COVID-19 severity correlation: COVID toes are usually associated with mild infection and strong immune response, not with severe respiratory disease.
Persistent or atypical cases warrant evaluation for autoimmune disorders, lupus, or chronic pernio.


Key References (Peer-Reviewed)
  1. Freeman EE, McMahon DE, Lipoff JB, et al. Pernio-like skin lesions associated with COVID-19: a case series of 318 patients from 8 countries. J Am Acad Dermatol. 2020;83(2):486–492.
  2. Colmenero I, Santonja C, Alonso-Riaño M, et al. SARS-CoV-2 endothelial infection causes COVID-19 chilblains: histopathological, immunohistochemical and ultrastructural study of seven paediatric cases. Br J Dermatol. 2020;183(4):729–737.
  3. Hubiche T, Cardot-Leccia N, Le Duff F, et al. Clinical, laboratory, and interferon-alpha response characteristics of patients with chilblain-like lesions during the COVID-19 pandemic. JAMA Dermatol. 2021;157(2):202–206.
  4. Andina D, Noguera-Morel L, Bascuas-Arribas M, et al. Chilblains in children in the setting of COVID-19 pandemic. Pediatr Dermatol. 2020;37(3):406–411.
  5. Freeman EE, McMahon DE, Fox LP, et al. The spectrum of COVID-19-associated dermatologic manifestations: an international registry of 716 patients from 31 countries. J Am Acad Dermatol. 2020;83(4):1118–1129.
  6. Fernandez-Nieto D, Jimenez-Cauhe J, Suarez-Valle A, et al. Characterization of acute acral skin lesions in nonhospitalized patients: a case series of 132 patients during the COVID-19 outbreak. J Am Acad Dermatol. 2020;83(1):e61–e63.
  7. Magro C, Mulvey JJ, Laurence J, et al. The differing pathophysiologies that underlie COVID-19-associated perniosis and thrombotic retiform purpura: a case series. Br J Dermatol. 2021;184(1):141–150.
​
Recommended DIY Products